Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

被引:38
作者
Ostrominski, John W. [1 ]
Vaduganathan, Muthiah [1 ]
Claggett, Brian L. [1 ]
de Boer, Rudolf A. [2 ]
Desai, Akshay S. [1 ]
Dobreanu, Dan [3 ]
Hernandez, Adrian F. [4 ,5 ]
Inzucchi, Silvio E. [6 ]
Jhund, Pardeep S. [7 ]
Kosiborod, Mikhail [8 ]
Lam, Carolyn S. P. [2 ,9 ,10 ]
Langkilde, Anna M. [11 ]
Lindholm, Daniel [11 ]
Martinez, Felipe A. [12 ]
O'Meara, Eileen [13 ]
Petersson, Magnus [11 ]
Shah, Sanjiv J. [14 ]
Thierer, Jorge [15 ]
McMurray, John J., V [7 ]
Solomon, Scott D. [1 ]
机构
[1] Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands
[3] Univ Med Pharm Sci & Technol GE Palade, Targu Mures, Romania
[4] Duke Univ, Dept Med, Durham, NC USA
[5] Duke Univ, Duke Clin Res Inst, Durham, NC USA
[6] Yale Univ, Sch Med, Sect Endocrinol, New Haven, CT USA
[7] Univ Glasgow, British Heart Fdn, Cardiovasc Res Ctr, Glasgow, Lanark, Scotland
[8] Univ Missouri Kansas City, St Lukes Mid Amer Heart Inst, Kansas City, MI USA
[9] Natl Heart Ctr Singapore, Singapore, Singapore
[10] Duke Natl Univ Singapore, Singapore, Singapore
[11] BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden
[12] Univ Nacl Cordoba, Cordoba, Argentina
[13] Univ Montreal, Inst Cardiol Montreal, Montreal, PQ, Canada
[14] Northwestern Univ, Feinberg Sch Med, Feinberg Cardiovasc Res Inst, Chicago, IL 60611 USA
[15] Ctr Educ Med & Invest Clin Norberto Quirno CEM, Unidad Insuficiencia Cardiaca, Buenos Aires, DF, Argentina
关键词
Dapagliflozin; Heart failure with preserved ejection fraction; Functional status; New York Heart Association classification; SGLT2; INHIBITORS; MORTALITY; OUTCOMES;
D O I
10.1002/ejhf.2652
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims This pre-specified analysis of the DELIVER trial examined whether clinical benefits of dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF) >40% varied by baseline New York Heart Association (NYHA) class and examined the treatment effects on NYHA class over time. Methods and results Treatment effects of dapagliflozin by baseline NYHA class II (n = 4713) versus III/IV (n = 1549) were examined on the primary endpoint (cardiovascular death or worsening HF event) and key secondary endpoints. Effects of dapagliflozin on change in NYHA class at 4, 16, and 32 weeks were also evaluated. Higher baseline NYHA class was associated with older age, female sex, greater comorbidity burden, lower LVEF, and higher natriuretic peptide levels. Participants with baseline NYHA class III/IV, as compared with II, were independently more likely to experience the primary endpoint (adjusted hazard ratio [HR] 1.16 [95% confidence interval, 1.02-1.33]) and all-cause death (adjusted HR 1.22 [1.06-1.40]). Dapagliflozin consistently reduced the risk of the primary endpoint compared with placebo, irrespective of baseline NYHA class (HR 0.81 [0.70-0.94] for NYHA class II vs. HR 0.80 [0.65-0.98] for NYHA class III/IV; p(interaction) = 0.921). Participants with NYHA class III/IV had greater improvement in Kansas City Cardiomyopathy Questionnaire total symptom scores between baseline and 32 weeks (+4.8 [2.5-7.1]) versus NYHA class II (+1.8 [0.7-2.9]; p(interaction) = 0.011). Dapagliflozin was associated with higher odds of any improvement in NYHA class (odds ratio [OR] 1.32 [1.16-1.51]), as well as improvement to NYHA class I (OR 1.43 [1.17-1.75]), versus placebo at 32 weeks, with benefits seen as early as 4 weeks. Conclusions Among symptomatic patients with HF and LVEF >40%, treatment with dapagliflozin provided clinical benefit irrespective of baseline NYHA class and was associated with early and sustained improvements in NYHA class over time.
引用
收藏
页码:1892 / 1901
页数:10
相关论文
共 33 条
[1]   Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function [J].
Ahmed, A ;
Aronow, WS ;
Fleg, JL .
AMERICAN HEART JOURNAL, 2006, 151 (02) :444-450
[2]   Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease [J].
Bansal, Nisha ;
Zelnick, Leila ;
Bhat, Zeenat ;
Dobre, Mirela ;
He, Jiang ;
Lash, James ;
Jaar, Bernard ;
Mehta, Rupal ;
Raj, Dominic ;
Rincon-Choles, Hernan ;
Saunders, Milda ;
Schrauben, Sarah ;
Weir, Matthew ;
Wright, Julie ;
Go, Alan S. ;
Appel, Lawrence J. ;
Feldman, Harold, I ;
Go, Alan S. ;
He, Jiang ;
Lash, James P. ;
Rao, Panduranga S. ;
Rahman, Mahboob ;
Townsend, Raymond R. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (21) :2691-2700
[3]   Expenditure on Heart Failure in the United States [J].
Bhatnagar, Roshni ;
Fonarow, Gregg C. ;
Heidenreich, Paul A. ;
Ziaeian, Boback .
JACC-HEART FAILURE, 2022, 10 (08) :571-580
[4]   Gliflozins in the Management of Cardiovascular Disease [J].
Braunwald, Eugene .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (21) :2024-2034
[5]   Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial [J].
Butler, Javed ;
Filippatos, Gerasimos ;
Siddiqi, Tariq Jamal ;
Brueckmann, Martina ;
Bohm, Michael ;
Chopra, Vijay K. ;
Ferreira, Joao Pedro ;
Januzzi, James L. ;
Kaul, Sanjay ;
Pina, Ileana L. ;
Ponikowski, Piotr ;
Shah, Sanjiv J. ;
Senni, Michele ;
Vedin, Ola ;
Verma, Subodh ;
Peil, Barbara ;
Pocock, Stuart J. ;
Zannad, Faiez ;
Packer, Milton ;
Anker, Stefan D. .
CIRCULATION, 2022, 145 (03) :184-193
[6]   Clinical Implications of the New York Heart Association Classification [J].
Caraballo, Cesar ;
Desai, Nihar R. ;
Mulder, Hillary ;
Alhanti, Brooke ;
Wilson, F. Perry ;
Fiuzat, Mona ;
Felker, G. Michael ;
Pina, Ileana L. ;
O'Connor, Christopher M. ;
Lindenfeld, Joanne ;
Januzzi, James L. ;
Cohen, Lawrence S. ;
Ahmad, Tariq .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (23)
[7]   Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry [J].
Chioncel, Ovidiu ;
Lainscak, Mitja ;
Seferovic, Petar M. ;
Anker, Stefan D. ;
Crespo-Leiro, Maria G. ;
Harjola, Veli-Pekka ;
Parissis, John ;
Laroche, Cecile ;
Piepoli, Massimo Francesco ;
Fonseca, Candida ;
Mebazaa, Alexandre ;
Lund, Lars ;
Ambrosio, Giuseppe A. ;
Coats, Andrew J. ;
Ferrari, Roberto ;
Ruschitzka, Frank ;
Maggioni, Aldo P. ;
Filippatos, Gerasimos .
EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (12) :1574-1585
[8]   Functional Status, Pulmonary Artery Pressure, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction [J].
Dalos, Daniel ;
Mascherbauer, Julia ;
Zotter-Tufaro, Caroline ;
Duca, Franz ;
Kammerlander, Andreas A. ;
Aschauer, Stefan ;
Bonderman, Diana .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (02) :189-199
[9]   Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction [J].
Edelmann, Frank ;
Stahrenberg, Raoul ;
Gelbrich, Goetz ;
Durstewitz, Kathleen ;
Angermann, Christiane E. ;
Duengen, Hans-Dirk ;
Scheffold, Thomas ;
Zugck, Christian ;
Maisch, Bernhard ;
Regitz-Zagrosek, Vera ;
Hasenfuss, Gerd ;
Pieske, Burkert M. ;
Wachter, Rolf .
CLINICAL RESEARCH IN CARDIOLOGY, 2011, 100 (09) :755-764
[10]   Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction [J].
Greene, Stephen J. ;
Butler, Javed ;
Spertus, John A. ;
Hellkamp, Anne S. ;
Vaduganathan, Muthiah ;
DeVore, Adam D. ;
Albert, Nancy M. ;
Duffy, Carol I. ;
Patterson, J. Herbert ;
Thomas, Laine ;
Williams, Fredonia B. ;
Hernandez, Adrian F. ;
Fonarow, Gregg C. .
JAMA CARDIOLOGY, 2021, 6 (05) :522-531